1. Search Result
Search Result
Results for "

PPARγ coactivator-1α

" in MedChemExpress (MCE) Product Catalog:

92

Inhibitors & Agonists

31

Natural
Products

5

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17538
    ZLN005
    30+ Cited Publications

    PGC-1α Autophagy Metabolic Disease
    ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) [1].
    ZLN005
  • HY-101491
    SR-18292
    40+ Cited Publications

    PGC-1α Autophagy Metabolic Disease
    SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
    SR-18292
  • HY-17538S

    PGC-1α Autophagy Metabolic Disease
    ZLN005-d4 is deuterium labeled ZLN005. ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α)[1].
    ZLN005-d4
  • HY-113960

    Estrogen Receptor/ERR Cancer
    ERRα antagonist-1 (Compound A) is a selective and high affinity estrogen-related receptor α (ERRα) antagonist. ERRα antagonist-1 inhibits interaction of ERRα with Proliferator-activated Receptor γ Coactivator-1α (PGC-1α) and PGC-1β, the IC50 values are 170 nM and 180 nM, respectively. ERRα antagonist-1 does not inhibit the interaction of either ERRβ or ERRγ with PGC-1α and PGC-1β coactivator, and also does not inhibit interaction of ERα or ERβ with PGC-1α or SRC-1 [1].
    ERRα antagonist-1
  • HY-147705

    PPAR Metabolic Disease
    PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binder with the IC50 of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC50 of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects [1].
    PPARγ phosphorylation inhibitor 1
  • HY-146480

    PPAR Cancer
    PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases [1].
    PPARγ agonist 5
  • HY-160159

    PPAR Metabolic Disease
    Anticancer agent 183 (example 48) is a non-agonistic PPARG modulator. Anticancer agent 183 has a high affinity to PPARG (PPARγ). Anticancer agent 183 inhibits kinase-mediated phosphorylation of PPARG. Anticancer agent 183 can used for research on metabolic diseases to avoid side effects [1].
    PPARγ modulator-1
  • HY-147511

    PPAR Others
    PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of PPARγ. PPARγ agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC50, 4.34 μM) [1].
    PPARγ agonist 7
  • HY-146438

    PPAR Cancer
    PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib [1].
    PPARγ agonist 3
  • HY-146439

    PPAR Cancer
    PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of PPARγ. PPARγ agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib [1].
    PPARγ agonist 4
  • HY-153982

    PPAR Metabolic Disease
    PPARγ agonist 8 is an agonist of PPARγ. PPARγ agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC50 of 0.2 μM [1].
    PPARγ agonist 8
  • HY-160003

    PPAR Metabolic Disease
    PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC50 more than 10 μM for LPA3 receptor [1].
    PPARγ agonist 9
  • HY-147757

    PPAR Metabolic Disease
    PPARγ/δ modulator 1 (compound 3e) is a potent PPAR modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with Ki values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC50 of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively [1].
    PPARγ/δ modulator 1
  • HY-146731

    PPAR Cardiovascular Disease Metabolic Disease
    PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders [1].
    PPARγ agonist 1
  • HY-106181A

    R-106056 hydrochloride

    PPAR Metabolic Disease
    Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes [1].
    Rivoglitazone hydrochloride
  • HY-15655
    GW1929
    5+ Cited Publications

    PPAR Neurological Disease Metabolic Disease
    GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential [1] .
    GW1929
  • HY-156010

    PPAR Metabolic Disease
    PPARγ-IN-2 (Compound 5a) is a PPARγ inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC50: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue [1].
    PPARγ-IN-2
  • HY-161985

    PPAR Metabolic Disease
    PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity [1].
    PPARγ-IN-3
  • HY-110022

    PPAR Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential [1] .
    GW1929 hydrochloride
  • HY-146742

    PPAR Metabolic Disease
    PPARγ agonist 2 is a potent PPARγ partial agonist and can be used for metabolic disease research [1].
    PPARγ agonist 2
  • HY-146482

    PPAR Cancer
    PPARγ agonist 6 (Compound 12) is a potent and selective agonist of PPARγ. PPARγ agonist 6 has the potential for the research of cancer diseases [1].
    PPARγ agonist 6
  • HY-163294

    PPAR Metabolic Disease
    PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells [1].
    PPARγ agonist 10
  • HY-116468

    PPAR Metabolic Disease
    PPARγ agonist 11 (compound 20) is a selective agonist of PPARγ (EC50: 0.1 μM) [1].
    PPARγ agonist 11
  • HY-162320

    PPAR Metabolic Disease
    PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC50s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect [1].
    PPARγ agonist 12
  • HY-N0246
    Saikosaponin A
    1 Publications Verification

    LXR Bacterial Inflammation/Immunology Cancer
    Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis [1] .
    Saikosaponin A
  • HY-151963

    PPAR Glucocorticoid Receptor Metabolic Disease
    PPARγ/GR modulator 1 is an orally active dual agonist of PPARγ and glucocorticoid receptor (GR), with Kis of 3.3 and 33.6 μM, respectively. PPARγ/GR modulator 1 can be used for the research of metabolic diseases, such as diabetes [1].
    PPARγ/GR modulator 1
  • HY-14831

    MBX 102; JNJ 39659100

    PPAR Metabolic Disease
    Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.
    Arhalofenate
  • HY-N2209

    PPAR Metabolic Disease
    Angeloylgomisin H, as a major lignin extract of Schisandra rubriflora, has the potential to improve insulin-stimulated glucose uptake by activating PPAR-γ [1].
    Angeloylgomisin H
  • HY-130479

    Adiponectin Receptor PPAR PGC-1α Sirtuin AMPK Metabolic Disease
    AdipoR agonist 1 (Compound 112254) is an agonist for adiponectin receptor (AdipoR), which activates the transcriptional regulators like peroxisome proliferator-activated receptors (PPARs), peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), sirtuin 1 (SIRT1), and adenylate-activated protein kinase (AMPK). AdipoR agonist 1 is utilized in preventive doping research [1].
    AdipoR agonist 1
  • HY-N0604
    Ginsenoside Rh1
    2 Publications Verification

    Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1

    Interleukin Related PPAR TNF Receptor Endogenous Metabolite Inflammation/Immunology
    Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
    Ginsenoside Rh1
  • HY-N4194

    PPAR Metabolic Disease
    Glabrone is an isoflavone isolated from Glycyrrhiza glabra roots. Glabrone exhibits anti-influenza activity and significant PPAR-γ ligand-binding activity [1] .
    Glabrone
  • HY-N0246R

    LXR Bacterial Metabolic Disease Inflammation/Immunology
    Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis [1] .
    Saikosaponin A (Standard)
  • HY-N3960

    PPAR Bacterial Infection Metabolic Disease
    Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity [1] .
    Glycyrin
  • HY-N11773

    PPAR Metabolic Disease
    Gancaonin L is an isoflavone, that can be isolated from Glycyrrhiza glabra roots. Gancaonin L exhibits significant PPAR-γ ligand-binding activity. Gancaonin L can be used for anti-diabetes and anti-obesity research [1].
    Gancaonin L
  • HY-120160

    CP-86325

    PPAR Neurological Disease Metabolic Disease
    Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research [1].
    Darglitazone
  • HY-W011309

    1-O-HDG; HXDG

    PPAR PGE synthase Inflammation/Immunology
    1-O-Hexadecylglycerol can up-regulate PPAR-γ expression, inhibit pGE2, and exhibit anti-inflammatory properties [1]. 1-O-Hexadecylglycerol is effective in oral administration .
    1-O-Hexadecylglycerol
  • HY-113473

    PPAR Metabolic Disease Inflammation/Immunology Cancer
    10-Nitrolinoleic acid is a potent peroxisome proliferator-activated receptor γ (PPARγ) agonist. 10-Nitrolinoleic acid competes with [ 3H]Rosiglitazone for binding to PPAR-γ, with an IC50 of 0.22 μM [1].
    10-Nitrolinoleic acid
  • HY-120160A

    CP 86325 Sodium

    PPAR Neurological Disease Metabolic Disease
    Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research [1] .
    Darglitazone Sodium
  • HY-156276

    PPAR Metabolic Disease
    SP4e is an activator of PPAR-γ, with the EC50 of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice [1].
    SP4e
  • HY-N0222
    Avicularin
    3 Publications Verification

    COX NF-κB PPAR ERK GLUT Apoptosis Infection Neurological Disease Inflammation/Immunology Cancer
    Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities [1] .
    Avicularin
  • HY-13956S

    U 72107-d4

    PPAR Ferroptosis Metabolic Disease Cancer
    Pioglitazone-d4 is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1].
    Pioglitazone-d4
  • HY-117727A

    MIN-102 hydrochloride; Hydroxypioglitazone hydrochloride

    PPAR Metabolic Disease
    Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a Ki of 1.2 μM,Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC50 of 680 nM [1].
    Leriglitazone hydrochloride
  • HY-139408

    17-Oxo-DHA; 17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-DHA

    PPAR Keap1-Nrf2 Metabolic Disease
    17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid (17-Oxo-DHA) is a metabolite of lipoxygenase-mediated oxidation of DHA. 17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid is a PPARγ agonist and activates a Nrf2 dependent antioxidant reaction [1].
    17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid
  • HY-169070

    PPAR Others
    Anti-osteoporosis agent-10 is an osteoporosis inhibitor. Anti-osteoporosis agent-10 can suppress the generation of osteoclasts, with an IC50 of 0.042 μM. Anti-osteoporosis agent-10 also has antagonistic activity on PPARγ, with an EC50 value of 0.75 μM [1].
    Anti-osteoporosis agent-10
  • HY-B0205
    Candesartan
    5 Publications Verification

    CV 11974

    Angiotensin Receptor PPAR Cardiovascular Disease Endocrinology Cancer
    Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) [1] .
    Candesartan
  • HY-N0625A
    Alpinetin
    4 Publications Verification

    PPAR Keap1-Nrf2 Toll-like Receptor (TLR) Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Alpinetin is a flavonoid isolated from cardamom and possesses antitumor, antiinflammation, hepatoprotective, cardiovascular protective, lung protective, antibacterial, antiviral, neuroprotective properties. Alpinetin inhibits lipopolysaccharide (LPS)-induced inflammation, activates PPAR-γ, activates Nrf2, and inhibits TLR4 expression to protect LPS-induced renal injury [1] .
    Alpinetin
  • HY-N6869

    Antibiotic PPAR Bacterial Fungal Infection Metabolic Disease Inflammation/Immunology Cancer
    Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice [1] .
    Dehydroabietic acid
  • HY-N0222R

    COX NF-κB PPAR ERK GLUT Apoptosis Infection Neurological Disease Inflammation/Immunology Cancer
    Avicularin (Standard) is the analytical standard of Avicularin. This product is intended for research and analytical applications. Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities [1] .
    Avicularin (Standard)
  • HY-19775

    ROR Inflammation/Immunology
    GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC50 value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC50 of 30 nM for IL-17 PBMC [1].
    GNE-6468
  • HY-122716

    PPAR Others
    PTGR2-IN-1 is a potent PTGR2 inhibitor with an IC50 of ~0.7 μM. PTGR2-IN-1 increases 15-keto-PGE2-dependent PPARγ transcriptional activity in PTGR2-transfected HEK293T cells [1].
    PTGR2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: